Delay, J, Deniker, P. Trente-huit cas de psychoses traités par le cure prolongé et continue de 4560RP. Le Congrès des Al. et Neurol. de Langue Fr. Comptes Rendus du Congres Paris. Masson, 1952.
Scarpitti, FR, Pasamanick, BS. Medication in schizophrenia. Arch Gen Psychiatry
1964; 10: 143.
Prien, RF, Cole, JO, Belkin, NF. Relapse in chronic schizophrenics following abrupt withdrawal of tranquillizing medication. Br J Psychiatry
1969; 115: 679–86.
Denham, J, Adamson, L. The contribution of fluphenazine enanthate and decanoate in the prevention of readmission of schizophrenic patients. Acta Psychiatr Scand
1971; 47: 420–30.
Johnson, DAW, Freeman, HL. Long-acting tranquillisers. Practitioner
1972; 208: 395–400.
Gottfries, GC, Green, L. Fluphenthixol decanoate – in treatment of outpatients. Acta Psychiatr Scand Suppl
1974; 225: 15–24.
Hogarty, GE, Goldberg, SC, Schooler, NR. Drug and sociotherapy in the aftercare of schizophrenic patients: one year relapse rates. Arch Gen Psychiatry
1973; 28: 54–64.
Hogarty, GE, Goldberg, SC, Schooler, NR. Drug and sociotherapy in the aftercare of schizophrenic patients: two year relapse rates. Arch Gen Psychiatry
1974; 31: 603–8.
Hogarty, GE, Ulrich, R, Goldberg, SC. Sociotherapy and the prevention of relapse among schizophrenic patients. In Evaluation of Psychological Therapies (eds Spitzer, RL, Klein, DF): 285–93. Johns Hopkins University Press, 1976.
Hirsch, SR, Gaind, R, Rhode, PD, Stevens, BC, Wing, JK. Outpatient maintenance of chronic schizophrenic patients with long acting phenothiazines. BMJ
1973; i: 633–7.
Davis, JM. Overview: maintenance therapy in schizophrenia. I. Schizophrenia. Am J Psychiatry
1975; 132: 1237–45.
Rifkin, A, Quitkin, F, Rabiner, CJ. Fluphenazine decanoate, fluphenazine hydrochloride given orally and placebo in remitted schizophrenia: relapse rate over one year. Arch Gen Psychiatry
1977; 34: 43–7.
Quitkin, F, Rifkin, A, Kane, J, Ramos-Lorenzi, JR, Klein, DF. Long-acting oral drugs vs. injectable antipsychotic drugs in schizophrenia: a one year double-blind comparison in multi episode schizophrenia. Arch Gen Psychiatry
1978; 35: 889–92.
Schooler, NR, Levine, J, Severe, JB, Brauzer, B, DiMascio, A, Klerman, GL, et al. Prevention of relapse in schizophrenia: an evaluation of fluphenazine decanoate. Arch Gen Psychiatry
1980; 37: 16–24.
Tegeler, J, Lehmann, E. A follow-up study of schizophrenic outpatients treated with depot neuroleptics. Prog Neuropsychopharmacol
1981; 5: 79–90.
Wistedt, B. A neuroleptic withdrawal study in chronic schizophrenic patients. Acta Psychiatr Scand
1981; 64: 65–84.
Kane, JM, Rifkin, A, Quitkin, F, Nayak, DV, Ramos-Lorenzi, JR. Fluphenazine versus placebo in patients with remitted, acute first episodes of schizophrenia. Arch Gen Psychiatry
1982; 39: 70–3.
Johnson, DAW. Depression: treatment compliance in general practice. Acta Psychiatr Scand Suppl
1983; 63 (suppl 290): 447–53.
Johnson, DAW. Observations on the use of long-acting depot neuroleptic injections in the maintenance treatment of schizophrenia. J Clin Psychiatry
1984; 45: 13–21.
Crow, TJ, McMillan, JF, Johnson, AL, Johnstone, EC. A randomised controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry
1986; 148: 120–7.
Pietzcker, A, Gaebel, W, Kopcke, W, Linden, M, Muller, P. A German multicenter study on the neuroleptic long-term therapy of schizophrenic patients. Pharmacopsychiatry
1986; 19: 161–6.
Hogarty, GE, Schooler, NR, Ulrich, R, Mussare, F, Ferro, P, Herron, E. Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch Gen Psychiatry
1979; 36: 1283–94.
Kissling, W, (ed). Neuroleptic relapse prevention. In Guidelines for Neuroleptic Relapse Prevention in Schizophrenia: 50–2. Springer, 1991.
Johnson, DAW. United Kingdom: neuroleptic relapse prevention. In Guidelines for Neuroleptic Relapse Prevention in Schizophrenia (ed Kissling, W): 45. Springer, 1991.
Dencker, SJ. Sweden: neuroleptic relapse prevention. In Guidelines for Neuroleptic Relapse Prevention in Schizophrenia (ed Kissling, W): 24. Springer, 1991.
Fleischhacker, WW, Meise, U. Austria: the current status of maintenance treatment in schizophrenia. In Guidelines for Neuroleptic Relapse Prevention in Schizophrenia (ed Kissling, W): 13. Springer, 1991.
Cooper, B, Shepherd, M. Life change, stress and mental disorder: the ecological approach. In Modern Trends in Psychological Medicine, 2nd edn (ed Price, JH): 102–30. Butterworth, 1970.
Pinel, P. A Treatise on Insanity (trans. Davis, D.). . Hafner, 1962.
Kendal, RE, Pighot, P, von Cranach, M. Diagnostic criteria of English, French and German psychiatrists. Psychol Med
1974; 4: 187–95.
Kendal, RE. The classification and phenomenology of schizophrenia: overview. In Contemporary Issues in Schizophrenia (ed Kerr, A, Snaith, P): 119–23. Gaskell, 1986.
Feigher, JP, Robins, E, Guze, S, Woodruff, RA, Winokur, G, Munoz, R. Diagnostic criteria for use in psychiatric research. Arch Gen Psychiatry
1972; 26: 57–63.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (3rd edn) (DSM–III). APA, 1980.
Leff, JP, Wing, JK. Trial of maintenance therapy in schizophrenia. BMJ
1971; 3: 599–604.
World Health Organization. The International Pilot Study of Schizophrenia, vol. 1. WHO, 1974.
Mandelbrote, BM. Schizophrenia: treatment and outcome. In Modern Trends in Psychological Medicine, 2nd edn (ed Price, JH): 200–22. Butterworth, 1970.
Greenblatt, M, York, RH, Brown, EL. From Custodial to Therapeutic Care in Mental Hospital. Russell Sage Foundation, 1955.
Bockhoven, JS. Moral treatment in American society. J Nerv Ment Dis
1956; 124: 167.
Standt, VM, Zubin, J. A biometric evaluation of the somatotherapies in schizophrenia – a critical review. Psychol Bull
1957; 5: 171.
Moniz, E. Tentatives Operatoires dans le Traitement de Certaines Psychoses. Masson, 1936.
Appel, KE, Lhamon, WT, Myers, JM, Harvey, WA. Long-term psychotherapy in psychiatric treatment. Res Publ Assoc Res Nerv Ment Dis
1953; 31: 21–41.
Wing, JK, Brown, GW. Social treatment of chronic schizophrenia: a comparative study of three mental hospitals. J Ment Sci
1961; 107: 847–61.
Birley, JLT, Brown, GW. Crises and life changes preceding the onset or relapse of acute schizophrenia: clinical aspects. Br J Psychiatry
1970; 116: 327–33.
Bebbington, PE, Kuipers, L. Social influences on schizophrenia. In Schizophrenia: The Major Issue (eds Bebbington, P, McGuffin, P): 202–25. Heinemann, 1988.
Greenblatt, M. Drugs in Combination with Other Therapies. Grune & Stratton, 1975.
Bebbington, P, McGuffin, P, (eds). Schizophrenia: The Major Issues. Heinemann, 1988.
Taylor, RDW, Huxley, PJ, Johnson, DAW. The role of social networks in the maintenance of schizophrenic patients. Br J Social Work
1984; 14: 129–40.
Freeman, HL, (ed). Psychiatric Hospital Care. Baillière Tindall & Cassell, 1965.
Freeman, HL, Johnson, DAW. Progress to community care in an English city
Pakistan Medical Forum
1970; 5: 25–34.
Davis, JM, Schaffer, CB, Kinard, C, Chan, C. Important issues in drug treatment of schizophrenia. Schizophr Bull
1980; 6: 70–87.
Kane, JM. Treatment of schizophrenia. Schizophr Bull
1987; 13: 133–56.
Barnes, TRE, Hirsch, SR. Neuroleptic relapse prevention. In Guidelines for Neuroleptic Relapse Prevention in Schizophrenia (ed Kissling, W). Springer, 1991.
Brown, GW, Birley, JLT, Wing, JK. Influence of family life on the course of schizophrenic disorders: a replication. Br J Psychiatry
1972; 121: 241–58.
Vaughn, CE, Leff, JP. The influence of family and social factors on the course of psychiatric illness. A comparison of schizophrenic and depressed neurotic patients. Br J Psychiatry
1976; 129: 125–37.
Hogarty, GE, Goldberg, SC, Schooler, NR. Drug and sociotherapy in the aftercare of schizophrenic patients. In Drugs in Combination with Other Therapies (ed Greenblatt, M): 1–34. Grune & Stratton, 1975.
Cutting, J. Outcome of schizophrenia: overview. In Contemporary Issues in Schizophrenia (eds Kerr, A, Snaith, P): 433–40. Gaskell, 1986.
Ley, P, Spelman, MS. Communicating with the Patient: 37–78. Staples Press, 1967.
Wilcox, DRC, Gillan, R, Hare, EH. Do psychiatric patients take their drugs?
1965; 2: 790–2.
Neve, HK. Demonstration of Largactil in the urine. J Ment Sci
1958; 104: 488–91.
Johnson, DAW. Treatment of depression in general practice. BMJ
1973; 2: 18–20.
Johnson, DAW. A study of the use of antidepressant medication in general practice. Br J Psychiatry
1974; 125: 186–92.
Johnson, DAW, Freeman, HL. Drug defaulting by patients on long-acting phenothiazines. Psychol Med
1973; 3: 115–9.
Baldessarini, RJ, Cohen, BM, Teicher, MH. Significance of neuroleptic dose and plasma level in the pharmacological treatments of psychoses. Arch Gen Psychiatry
1988; 45: 79–81.
Hogarty, GE, Ulrich, RF, Mussare, F, Austigueta, N. Drug discontinuation among long term successfully maintained schizophrenic outpatients. Dis Nerv Syst
1976; 37: 494–500.
Wistedt, B. A depot neuroleptic withdrawal study. Acta Psychiatr Scand
1981; 64: 65–84.
Marder, SR, van Putten, R, Mintz, J, Lebell, M, McKenzie, J, May, PRA. Low and conventional maintenance therapy with fluphenazine decanoate. Arch Gen Psychiatry
1987; 44: 518–22.
Kissling, W, Kane, JM, Barnes, TRE, Dencker, ST, Fleischhacker, WW, Goldstein, MJ, et al. In Guidelines for Neuroleptic Relapse Prevention in Schizophrenia (ed Kissling, W). Springer, 1991.
Johnson, DAW. The side-effects of fluphenazine decanoate. Br J Psychiatry
1973; 123: 519–22.
Johnson, DAW. Long term drug treatment of psychoses: observations on some current issues. Int Rev Psychiatry
1990; 2: 341–53.
British Medical Association, Royal Pharmaceutical Society. British National Formulary. . BMJ Books/Pharmaceutical Press, 2008.
Johnson, DA. Studies of depressive symptoms in schizophrenia. Br J Psychiatry
1981; 139: 89–101.
Johnson, DA. The significance of depression in the prediction of relapse in chronic schizophrenia. Br J Psychiatry
1988; 152: 320–3.
Johnson, DAW. Long term treatment of psychoses; observations on some current issues. Int Rev Psychiatry
1990; 2: 341–53.
McGlashen, TH, Carpenter, WT. Postpsychotic depression in schizophrenia. Arch Gen Psychiatry
1976; 33: 231–39.
McGlashen, TH, Carpenter, WT. An investigation of the postpsychotic depressive syndrome. Am J Psychiatry
1976; 133: 14–9.
Knights, A, Hirsch, SR. Revealed depression and drug treatment for schizophrenia. Arch Gen Psychiatry
1981; 38: 806–11.
Mandel, MR, Severe, JB, Schooler, NR. Development and prediction of postpsychotic depression in neuroleptic treated schizophrenia. Arch Gen Psychiatry
1982; 39: 197–203.
Roy, A. Risk factor for suicide in psychiatric patients. Arch Gen Psychiatry
1982; 39: 1089–95.
Van Putten, T, May, PRA. Akinetic depression in schizophrenia. Arch Gen Psychiatry
1978; 45, 1101–7.
Herz, MI, Melville, C. Relapse in schizophrenia. Am J Psychiatry
1980; 137: 801–5.
Carpenter, WR, Heinrich, DW, Hanlon, TE. A comparative trial of pharmacologic strategies in schizophrenia. Am J Psychiatry
1987; 144: 1466–70.
Brockington, IF, Kendell, RE, Kellett, JM, Curry, SH, Wainwright, S. Trial of lithium, chlorpromazine and amitriptyline in schizoaffective patients. Br J Psychiatry
1978; 133: 162–8.
Brockington, IF, Kendell, RE, Leff, JP. Prognostic implications of six alternative definitions of schizophrenia. Arch Gen Psychiatry
1979; 36: 25–31.
Siris, SG. Antidepressants in ‘depressed’ schizophrenics. In Depression in Schizophrenia (eds Williams, R, Dalby, JT): 215–32. Plenum, 1989.
Johnson, DAW, Wright, NK. Drug prescribing for schizophrenic out-patients on depot injections: repeat surveys over 18 years. Br J Psychiatry
Johnson, DAW, Rasmussen, JGC. Professional attitudes in the UK towards neuroleptic maintenance therapy in schizophrenia. The problem of inadequate prophylaxis. Psychiatr Bull
1997; 21: 394–7.
Kissling, W. Ideal and reality of neuroleptic relapse prevention. Br J Psychiatry
1992; 161 (suppl 18): 133–9.
Cassey, DS. Relationship of pharmacology to side effects. J Clin Psychiatry
1997; 58 (suppl 10): 55–62.
Correl, CU, Leucht, S, Kane, JM. Lower risk for TD associated with secondary generation antipsychotics; a systematic review of 1 year studies. Am J Psychiatry
2004; 161: 414–25.
Bagnall, AM, Jones, L, Ginelly, L, Lewis, R, Glanville, J, Gilbody, S, et al. A systematic review of atypical antipsychotics in schizophrenia. Health Technol Assess
2008; 7: 13.
Jones, PB, Barnes, TRE, Davies, L. Randomised controlled trial of the effect on quality of life of second vs first generation antipsychotic drugs in schizophrenia. Arch Gen Psychiatry
2006; 63: 1079–87.
Shirzadi, AA, Ghaemi, SN. Side-effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome. Harv Rev Psychiatry
2006; 14: 152–64.
Blom-Cooper, LJ, Hally, H, Murphy, E. The Falling Shadow: One Patient's Mental Healthcare 1978–1993. Report of the Committee of Inquiry into the Events Leading up to and Surrounding the Fatal Incident at the Edith Morgan Centre, Torbay, on 1 September 1993. Duckworth, 1995.
Thornicroft, G. National Service Framework for Mental Health. Psychiatr Bull
2000; 24: 203–6.
Patel, M, Nikolaou, V, David, AS. Eliciting psychiatrists' beliefs about side effects of typical and atypical antipsychotic drugs. Int J Psychiatry Clin Pract
2003; 7: 117–20.
Patel, MX, David, AS. Why aren't depot antipsychotics prescribed more often and what can be done about it?
Adv Psychiatr Treat
2005; 11: 203–11.